Published online before print March 11, 2002, doi: 10.1161/01.CIR.0000013839.41224.1C
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;105:1551.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1ß and Anti-erbB2
Potential Mechanism for Trastuzumab-Induced Cardiotoxicity
From the Cardiovascular Medicine Section, Department of Medicine, Boston Medical Center and Myocardial Biology Unit, Boston University School of Medicine, Boston, Mass (D.B.S., T.A.M.), and the Institute of Cell Biology, Swiss Federal Institute of Technology, Zurich, and Swiss Cardiovascular Center Bern, Inselspital, Bern, Switzerland (C.Z., H.M.E., T.M.S.).
Correspondence to Thomas M. Suter, MD, Cardiology, Inselspital, CH-3010 Bern, Switzerland. E-mail thomas.m.suter{at}insel.ch
Background— There is an increased incidence of heart failure in patients treated concurrently with anthracyclines and the chemotherapeutic anti-erbB2 agent trastuzumab (Herceptin). On the basis of our previous studies with recombinant neuregulin-1ß (NRG-1ß), a ligand for the erbB2 receptor tyrosine kinase, we hypothesized that activation of erbB2 by anti-erbB2 versus NRG-1 would cause differential effects on myocyte intracellular signaling as well as anthracycline-induced myofibrillar injury and might potentially account for the clinical toxicity of trastuzumab in the setting of concurrent anthracycline therapy.
Methods and Results— We tested this hypothesis using adult rat ventricular myocytes (ARVMs) in culture, assessing myofibrillar structure by immunostaining for myomesin and filamentous actin. Activation of erbB2, extracellular signal–regulated kinase 1/2 (Erk1/2), and Akt was assessed by use of antibodies to phosphorylated activated receptor or kinase detected by immunoblot. ARVMs treated with doxorubicin (0.1 to 0.5 µmol/L) showed a concentration-dependent increase in myofilament disarray. NRG-1ß (10 ng/mL) activated erbB2, Erk1/2, and Akt in ARVMs and significantly reduced anthracycline-induced disarray. In contrast to NRG-1ß, anti-erbB2 (1 µg/mL) caused rapid phosphorylation of erbB2 but not Erk1/2 or Akt, with downregulation of erbB2 by 24 hours. Concomitant treatment of myocytes with anti-erbB2 and doxorubicin caused a significant increase in myofibrillar disarray versus doxorubicin alone.
Conclusions— NRG-1ß/erbB signaling regulates anthracycline-induced myofilament injury. The increased susceptibility of myofilaments to doxorubicin in the presence of antibody to erbB2 may explain the contractile dysfunction seen in patients receiving concurrent trastuzumab and anthracyclines.
Key Words: erbB2 • cardiotoxicity • neuregulins • anthracyclines • myocytes
This article has been cited by other articles:
 |
|
 |
|
  Y. Bian, M. Sun, M. Silver, K. K. L. Ho, M. A. Marchionni, A. O. Caggiano, J. R. Stone, I. Amende, T. G. Hampton, J. P. Morgan, et al. Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H1974 - H1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T.H. Yeh and C. L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2231 - 2247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Wonders and B. S. Reigle Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise Integr Cancer Ther, March 1, 2009; 8(1): 17 - 21. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Ann. Onc., September 1, 2008; 19(9): 1530 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. E.A. Appelman and P. A. Doevendans Proteasome inhibition and stress compromise the heart in chemotherapy Cardiovasc Res, September 1, 2008; 79(4): 547 - 548. [Full Text] [PDF]
|
|
|
|
|
|
Y. Belkacemi, J. Gligorov, M. Ozsahin, H. Marsiglia, B. De Lafontan, H. Laharie-Mineur, L. Aimard, E.-C. Antoine, B. Cutuli, M. Namer, et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study Ann. Onc., June 1, 2008; 19(6): 1110 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R.J. H. Bird and S. M. Swain Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res., January 1, 2008; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Suter, M. Procter, D. J. van Veldhuisen, M. Muscholl, J. Bergh, C. Carlomagno, T. Perren, R. Passalacqua, C. Bighin, J. G.M. Klijn, et al. Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial J. Clin. Oncol., September 1, 2007; 25(25): 3859 - 3865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lemmens, K. Doggen, and G. W. De Keulenaer Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure Circulation, August 21, 2007; 116(8): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Perik, M. N. Lub-De Hooge, J. A. Gietema, W. T.A. van der Graaf, M. A. de Korte, S. Jonkman, J. G.W. Kosterink, D. J. van Veldhuisen, D. T. Sleijfer, P. L. Jager, et al. Indium-111-Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer J. Clin. Oncol., May 20, 2006; 24(15): 2276 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-F. Liu, J. R. Stone, A. J. T. Schuldt, K. Okoshi, M. P. Okoshi, M. Nakayama, K. K. L. Ho, W. J. Manning, M. A. Marchionni, B. H. Lorell, et al. Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H660 - H666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-N. Giraud, M. Fluck, C. Zuppinger, and T. M. Suter Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1{beta} J Appl Physiol, July 1, 2005; 99(1): 313 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE Mol. Interv., June 1, 2005; 5(3): 163 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Ewer and S. M. Lippman Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity J. Clin. Oncol., May 1, 2005; 23(13): 2900 - 2902. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Peng, X. Guo, S. C. Borkan, A. Bharti, Y. Kuramochi, S. Calderwood, and D. B. Sawyer Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in Myocytes J. Biol. Chem., April 1, 2005; 280(13): 13148 - 13152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kuramochi, G. M. Cote, X. Guo, N. K. Lebrasseur, L. Cui, R. Liao, and D. B. Sawyer Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1{beta}/erbB4 Signaling J. Biol. Chem., December 3, 2004; 279(49): 51141 - 51147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L'Ecuyer, Z. Allebban, R. Thomas, and R. Vander Heide Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2057 - H2064. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. FOGLI, P. NIERI, and M. C. BRESCHI The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J, April 1, 2004; 18(6): 664 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Lim, C. Zuppinger, X. Guo, G. M. Kuster, M. Helmes, H. M. Eppenberger, T. M. Suter, R. Liao, and D. B. Sawyer Anthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes J. Biol. Chem., February 27, 2004; 279(9): 8290 - 8299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lemmens, P. Fransen, S. U. Sys, D. L. Brutsaert, and G. W. De Keulenaer Neuregulin-1 Induces a Negative Inotropic Effect in Cardiac Muscle: Role of Nitric Oxide Synthase Circulation, January 27, 2004; 109(3): 324 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Plum, A. D. Hanson, K. M. Volker, H. A. Vu, B. K. L. Sim, W. E. Fogler, and A. H. Fortier Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model Clin. Cancer Res., October 1, 2003; 9(12): 4619 - 4626. [Abstract] [Full Text] [PDF]
|
|